Citi on Hims and Hers (HIMS): 'Will Enter the Canadian Market in 2026 as Generic Semaglutide Looms'
Tweet Send to a Friend
Citi analyst Daniel Grosslight reiterated a Sell rating and $30.00 price target on Hims and Hers (NYSE: HIMS).The analyst comments ...
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
